Lucio Leprosy with Lucio's phenomenon, digital gangrene and anticardiolipin antibodies.

Lucio's phenomenon (LPh) is considered a necrotizing panvasculitis and a variant of leprosy Type 2 reaction, clinically characterised by necrotic-haemorrhagic lesions on the extremities and trunk. LPh is observed in diffuse lepromatous leprosy (DLL or Lucio-Latapí leprosy). This is a distinct form of lepromatous leprosy (LL) reported mainly in Mexico. Anti-phospholipid antibody syndrome (APS) has been rarely described in LPh. We report a case of Lucio-Latapí leprosy with LPh observed in a patient from the province of El Oro in Ecuador, who presented clinical manifestations of long standing DLL (non-nodular infiltration of the skin, collapse of the nasal pyramid, madarosis, atrophy of the earlobes), of LPh (necrotic-haemorrhagic macules with irregular shapes) and of APS (necrosis of the right big and second toe). Histopathology showed perineural and periadnexal foamy macrophages with numerous bacilli (diagnostic of LL) in the subcutis, a mild lobular panniculitis with a large subcutaneous vessel infiltrated by macrophages in the wall (typical of LPh) and vessels of the superficial and mid dermis occluded by thrombi but without signs of vasculitis (typical of occlusive vasculopathy as in APS). Our observations suggest that some cases of LPh may be associated with APS. Anti-cardiolipin antibodies (aCL) and lupus anticoagulant (LA) should be tested in patients with LPh because this may have therapeutic implications.

[1]  L. P. V. Cardoso,et al.  Multibacillary leprosy patients with high and persistent serum antibodies to leprosy IDRI diagnostic-1/LID-1: higher susceptibility to develop type 2 reactions , 2015, Memorias do Instituto Oswaldo Cruz.

[2]  I. Estrada-García,et al.  Lepromatous leprosy patients produce antibodies that recognise non-bilayer lipid arrangements containing mycolic acids. , 2012, Memorias do Instituto Oswaldo Cruz.

[3]  J. S. Velarde-Félix,et al.  The leprosy agents Mycobacterium lepromatosis and Mycobacterium leprae in Mexico , 2012, International journal of dermatology.

[4]  H. Tan,et al.  Identification of the leprosy agent Mycobacterium lepromatosis in Singapore. , 2012, Journal of drugs in dermatology : JDD.

[5]  J. Fernández‐Díez,et al.  Lucio's Phenomenon Is a Necrotizing Panvasculitis: Mostly a Medium-Sized Granulomatous Arteritis , 2008, The American Journal of dermatopathology.

[6]  J. Spencer,et al.  A new Mycobacterium species causing diffuse lepromatous leprosy. , 2008, American journal of clinical pathology.

[7]  F. Vargas‐Ocampo Diffuse leprosy of Lucio and Latapí: a histologic study. , 2007, Leprosy review.

[8]  L. Azulay-Abulafia,et al.  [Lucio phenomenon. Vasculitis or occlusive vasculopathy?]. , 2006, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[9]  S. Akerkar,et al.  Leprosy & gangrene: A rare association; role of anti phospholipid antibodies , 2005, BMC infectious diseases.

[10]  R. Asherson,et al.  Anticardiolipin, anti-β2-glycoprotein I and antiprothrombin antibodies in black South African patients with infectious disease , 2003, Annals of the rheumatic diseases.

[11]  S. Ng,et al.  Fatal Lucio's phenomenon in 2 patients with previously undiagnosed leprosy. , 2003, Journal of the American Academy of Dermatology.

[12]  L. Carreras,et al.  High prevalence of antiphospholipid antibodies in leprosy: evaluation of antigen reactivity , 2000, Lupus.

[13]  G. Hughes,et al.  Antiphospholipid antibodies in leprotic patients: a correlation with disease manifestations. , 2000, Clinical and experimental rheumatology.

[14]  E. Nunzi,et al.  beta 2-Glycoprotein I-dependence of anticardiolipin antibodies in multibacillary leprosy patients. , 1998, Leprosy review.

[15]  E. Housley Anti phospholipid syndrome. , 1995, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[16]  Y. Shoenfeld,et al.  Anticardiolipin Antibodies in Infections are Heterogenous in Their Dependency on β 2-Glycoprotein I: Analysis of Anticardiolipin Antibodies in Leprosy , 1994, Lupus.

[17]  S. Kaur,et al.  Vascular involvement in leprosy. , 1989, Indian journal of leprosy.

[18]  Ridley Ds,et al.  Classification of leprosy according to immunity. A five-group system. , 1966 .

[19]  J. Jessurun,et al.  Severe leprosy reactions due to Mycobacterium lepromatosis. , 2013, The American journal of the medical sciences.

[20]  M. Magaña Lucio’s Phenomenon , 2012 .

[21]  E. Sato,et al.  Anti-β2-glycoprotein I antibodies are highly prevalent in a large number of Brazilian leprosy patients. , 2011, Acta reumatologica portuguesa.

[22]  Chan Jun-mi,et al.  International Consensus Statement on an Update of the Classification Criteria for Definite Antiphospholipid Syndrome(APS) , 2008 .

[23]  D. N. Cohen Granulomatous arteritis. , 1975, Comprehensive therapy.

[24]  A. Carayon,et al.  [A type of nonspecific nerve lesion in lepers]. , 1970, Bulletin de la Societe medicale d'Afrique noire de langue francaise.

[25]  D. Ridley,et al.  Classification of leprosy according to immunity. A five-group system. , 1966, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

[26]  F. Latapí,et al.  The " Spotted " Leprosy of Lueio (La lepra " Manchada " de Lucio). An Introduction to its Clinical and Histological Study. , 1948 .